Catalent Signs Agreement with Johnson & Johnson to be U.S. Manufacturing Partner for Lead COVID-19 Vaccine Candidate
- Collaboration includes joint investment and tech transfer to prepare for rapid scale-up and segregated cGMP commercial manufacturing capacity
- Catalent to hire 300 additional personnel to meet operational readiness and 24?7 manufacturing schedules